Circulating white blood cell traits and colorectal cancer risk: A Mendelian randomization study

Andrei-Emil Constantinescu^{1,2,3*}, Caroline J Bull^{1,2,3}, Nicholas Jones⁴, Ruth Mitchell^{1,2},
Kimberley Burrows^{1,2}, Niki Dimou⁵, Stéphane Bézieau⁶, Hermann Brenner^{7,8,9}, Daniel D
Buchanan^{10,110,12}, Mauro D'Amato^{13,14,15}, Mark A Jenkins¹⁶, Victor Moreno^{17,18,19,20}, Rish K
Pai²¹, Caroline Y Um²², Emily White^{4,24}, Neil Murphy⁵, Marc Gunter⁵, Nicholas J Timpson^{1,2}
Jeroen R Huyghe^{22§} and Emma E Vincent^{1,2,3§}

- 8
- ¹MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK
- ²Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK
- ³School of Translational Health Sciences, Bristol Medical School, University of Bristol,
- 12 Bristol, United Kingdom
- ⁴Institute of Life Science, Swansea University Medical School, Swansea, United Kingdom

⁵Nutrition and Metabolism Branch, International Agency for Research on Cancer, World

- 15 Health Organization, Lyon, France
- ⁶Service de Génétique Médicale, Centre Hospitalier Universitaire (CHU) Nantes, Nantes,
 France
- ⁷Division of Clinical Epidemiology and Aging Research, German Cancer Research Center
 (DKFZ), Heidelberg, Germany
- ⁸Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National
 Center for Tumor Diseases (NCT), Heidelberg, Germany
- ⁹German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ),
 Heidelberg, Germany
- ¹⁰Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of
 Melbourne, Parkville, Victoria 3010 Australia
- ¹¹University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer
 Centre, Parkville, Victoria 3010 Australia
- ¹²Genetic Medicine and Family Cancer Clinic, The Royal Melbourne Hospital, Parkville,
 Victoria, Australia
- ¹³Department of Medicine and Surgery, LUM University, Casamassima, Italy
- 31 ¹⁴Gastrointestinal Genetics Lab, CIC bioGUNE BRTA, Derio, Spain
- ¹⁵Ikerbasque, Basque Foundation for Science, Bilbao, Spain
- ¹⁶Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global
- 34 Health, The University of Melbourne, Melbourne, Victoria, Australia

- ¹⁷Oncology Data Analytics Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet
- 36 de Llobregat, Barcelona, Spain
- ¹⁸CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
- ¹⁹Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona,
 Spain
- 40 ²⁰ONCOBEL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de
- 41 Llobregat, Barcelona, Spain
- ²¹Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale,
 Arizona, USA
- ²²Department of Population Science, American Cancer Society, Atlanta, Georgia, USA
- ²³Department of Epidemiology, University of Washington School of Public Health, Seattle,
 Washington, USA
- 47 ²⁴Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington,
- 48 USA
- 49 [§]These authors contributed equally.
- 50 *Corresponding author:
- 51 Andrei-Emil Constantinescu, Oakfield House, Oakfield Grove, Bristol, United Kingdom,
- 52 BS8 2BN, +44 (0) 117 928 7274, andrei.constantinescu@bristol.ac.uk

54 Abstract

55 Observational studies have suggested a protective role for eosinophils in colorectal cancer 56 (CRC) development and implicated neutrophils, but the causal relationships remain unclear. 57 Here, we aimed to estimate the causal effect of circulating white blood cell (WBC) counts (N 58 = ~550,000) for basephils, eosinophils, monocytes, lymphocytes and neutrophils on CRC risk 59 (N = 52,775 cases and 45,940 controls) using Mendelian randomization (MR). For 60 comparison, we also examined this relationship using individual-level data from UK Biobank 61 (4,043 incident CRC cases and 332,773 controls) in a longitudinal cohort analysis. The 62 inverse-variance weighted (IVW) MR analysis suggested a protective effect of increased 63 basophil count and eosinophil count on CRC risk [OR per 1-SD increase: 0.88, CI(95%): 64 0.78-0.99, P=0.04; OR: 0.93, CI(95%): 0.88-0.98, P=0.01]. The protective effect of 65 eosinophils remained [OR per 1-SD increase: 0.88, CI(95%): 0.80-0.97, P=0.01] following 66 adjustments for all other WBC subtypes, to account for genetic correlation between the traits, 67 using multivariable MR. A protective effect of increased lymphocyte count on CRC risk was 68 also found [OR: 0.84, CI(95%): 0.76-0.93, P=6.70e-4] following adjustment. Consistent with 69 MR results, a protective effect for eosinophils in the cohort analysis in the fully adjusted 70 model [RR per 1-SD increase: 0.96, CI(95%): 0.93-0.99, P=0.02] and following adjustment 71 for the other WBC subtypes [RR: 0.96, CI(95%): 0.93-0.99, P=0.001] was observed. Our 72 study implicates peripheral blood immune cells, in particular eosinophils and lymphocytes, in 73 CRC development, highlighting a need for mechanistic studies to interrogate these 74 relationships.

75

What is already known of this topic – While previous observational studies have suggested
a protective role for eosinophils in colorectal cancer development and implicated neutrophils,

whether changes in the levels of circulating white blood cells causes colorectal cancer has notbeen explored.

80 What this study adds – Our study is the first to use Mendelian randomization (MR) to 81 investigate this relationship. In parallel, for comparison, we also conduct the largest cohort 82 study to date on the topic. We found evidence to suggest that elevated eosinophil and 83 lymphocyte count may have a protective effect on CRC risk, adding new insights into the 84 pathogenesis of CRC.

How this study might affect research, practice or policy – Our findings will encourage
further mechanistic exploration to understand the biological mechanisms underpinning our
findings, which may lead to new therapeutic approaches or risk reduction strategies.

88

89

90 Keywords

91 Mendelian randomization, UK Biobank, Colorectal cancer, GWAS, White blood cell count,92 Eosinophils

93

94 Introduction

95 Colorectal cancer (CRC) accounts for over 10% of all worldwide cancer cases and is the 96 second leading cause of cancer-related deaths globally [1–3]. Overall, the number of CRC 97 cases is rising [4] and is alarmingly on the rise in younger people (aged <50 years) [5–7]. 98 Given current challenges, and the estimation that 50% of CRC cases may be preventable [8],

99 a focus on identifying novel risk factors, and subsequent prophylactic and treatment options100 is warranted to limit the future healthcare burden.

101

102 White blood cells (WBCs) are commonly measured in routine blood tests and are divided into 103 five subtypes: basophils, eosinophils, lymphocytes, monocytes and neutrophils [9]. 104 Alterations to circulating WBC counts, have been found to play a role in disease risk, 105 severity, and progression, CRC development and mortality [10-15]. For example, higher 106 circulating counts of basophils and eosinophils, cells with a role in IgE-mediated immunity, 107 have been associated with reduced CRC risk and increased survival [16–20]. Higher absolute 108 lymphocyte count [such as T, B and natural killer (NK) cells] has also been associated with 109 better overall survival of CRC [21,22]. By contrast, a high absolute monocyte count was 110 found to be associated with worse CRC survival [21,22], consistent with their potential role 111 in tumour progression and metastasis [23]. Finally, neutrophils, a critical part of the innate 112 immune system [24], have also been associated with poor CRC overall survival [21,22].

113

114 Traditional (i.e. cross-sectional, case-control or cohort) studies account for the majority of 115 epidemiologic analyses undertaken on CRC, which can suffer from certain limitations, such 116 as confounding and reverse causation which can bias effect estimates [25,26]. Mendelian 117 randomization (MR) is a method in genetic epidemiology which could overcome these issues 118 by using single-nucleotide polymorphisms (SNPs) to proxy for an exposure of interest to 119 estimate the effect of an exposure on an outcome [27,28]. It operates akin to a randomized 120 control trial (RCT), as alleles are randomly assigned at birth [29]. We have used MR to 121 estimate the total effect of each WBC trait on CRC [30], and, to account for corelation

between WBC traits, multivariable (MV) MR to estimate the direct effect of these exposureson CRC by adjusting for their shared genetic architecture [30].

124

In this study we aimed to investigate the relationship between circulating WBC subtypes and CRC incidence. Firstly, an MR analysis was undertaken using the most comprehensive genome-wide association study (GWAS) for both WBC subtype counts and incident CRC available. Secondly, for comparison, we ran the largest longitudinal cohort study between WBCs and CRC to date using UK Biobank. Together these analyses allow us to compare between genetically proxied and observational estimates to thoroughly explore the relationship between circulating WBC counts and CRC development.

132

133 Methods

134 Study design

135 We aimed to investigate the relationship between circulating WBCs and CRC using a genetic 136 epidemiologic and complementary observational approach. First, MR analyses were 137 undertaken to estimate the effect of WBC subtype counts on CRC. We then performed a 138 multivariable MR (MVMR) analysis where the direct effect of each WBC subtype count was 139 estimated by adding all five WBC subtypes into the model (Figure 1A). STROBE-MR 140 guidelines were followed (STROBE-MR Supplement) [31]. Here, units were interpreted as 141 odds ratio (OR) for CRC per a normalized standard deviation (1-SD) increase in WBC count. 142 Next, a prospective longitudinal cohort study was undertaken using UK Biobank individual-143 level data. Here, subtype specific WBC counts were studied individually, and then each was 144 adjusted for each of the other traits (Figure 1B). STROBE guidelines were followed

- 145 (STROBE Supplement). Here, units were interpreted as risk ratio (RR) for CRC per a
- 146 normalized standard deviation (1-SD) increase in WBC count.

147



¹Chen et al. (https://doi.org/10.1016/j.cell.2020.06.045); ²Huyghe et al. (https://doi.org/10.1038/s41588-018-0286-6 & http://dx.doi.org/10.1136/gutjni-2020-321534); ³UK Biobank (https://doi.org/10.1038/s41586-018-0579-e)

148

Figure 1. Study design. We triangulated findings from two study designs: a Mendelian
randomization analysis(A) and a longitudinal cohort analysis (B) to estimate the casual effect
of WBC on CRC risk.

152

153 WBC count GWAS data

Summary statistics for WBC subtype counts were obtained from the "Blood Cell Consortium" (BCX) meta-analysis, the largest study being UKBB (N=~562,243) [32]. Genetic sex, age, age², study-specific covariates and PCs 1 to 10 were used as covariates. A brief description of each study included in the meta-analysis is available in **Supplementary Table 1**. Only variants which did not display heterogenous effect across studies were selected. Specific details on QC steps and association testing are available in the source

manuscripts. Summary statistics for WBC counts were downloaded from: http://www.mhihumangenetics.org/en/resources/.

162

163 CRC GWAS data

164 GWAS summary statistics for overall CRC risk and by anatomical subsite were taken from 165 the most comprehensive meta-analyses to date [33]: colon cancer (split into proximal and 166 distal colon cancer) and rectal cancer. Sixty-six studies, which include those of the Genetics 167 and Epidemiology of Colorectal Cancer Consortium (GECCO), Colorectal Cancer 168 Transdisciplinary Study (CORECT), and Colon Cancer Family Registry (CCFR) consortia 169 were meta-analysed [34–36]. The final sample was predominantly of European ancestry with 170 5.36% of East Asian ancestry. These were included due to their similar genetic architecture 171 with regards to CRC risk [37]. Genetic sex, age, study-specific variables and PCs were used 172 as covariates. An overview of all consortia included in the CRC meta-analysis is available in 173 **Supplementary Table 2,** and a breakdown of the sample sizes for each set of CRC summary 174 statistics is presented in Supplementary Table 3.

175

176 Genetic data processing

To select valid MR instruments, summary statistics for exposures were processed using the "TwoSampleMR" R package [38,39]. The presence of correlated instruments, i.e. those in linkage disequilibrium (LD), can bias MR estimates [40]. Therefore, the exposure SNPs were clumped (r^2 =0.001, window=10Mb, P-value threshold=5e-8) using the 1000 Genomes European dataset [41] as a reference panel. Following this step, the exposure and outcome datasets were "harmonised" i.e. had their effect alleles placed on the same reference strand [42]. SNPs with incorrect but unambiguous strand references were corrected, while those

184 with ambiguous strand references were removed. Similarly, palindromic SNPs with inferable185 strands were kept.

186

187 MR analysis of WBC counts on CRC risk

188 Primary MR analyses were undertaken using the inverse-variance weighted (IVW) method, 189 which is the fixed-effects meta-analysis of the estimated effect of all exposure SNPs on the 190 CRC outcome [43]. Conditional F-statistics were calculated to detect weak instrument bias 191 [44] for each exposure SNP as previously described [45]. Several sensitivity analyses were 192 undertaken to compare with the main IVW estimates. The presence of vertical pleiotropy i.e. 193 when a trait is downstream of the genetic variant but on the same biological pathway as the 194 exposure [46], was measured using Cochran's Q heterogeneity test [47]. Horizontal 195 pleiotropy, when some or all instruments for a trait acts through a different pathway to the 196 exposure [46], can violate one of the main MR assumptions. A number of sensitivity MR 197 analyses were undertaken to identify horizontal pleiotropy: MR-Egger (where the regression 198 intercept is not constrained to zero) [48], Weighted median (the median of all SNP ratio 199 estimates, where each ratio is weighted by the inverse of the variance) [49], Weighted mode 200 (assumes that the most frequent estimate in a set of instruments is zero) [50] and MR-201 PRESSO (detects individual SNPs contributing to horizontal pleiotropy) [51]. The direction 202 of the causal relationship between WBC traits and CRC risk was tested using the MR Steiger 203 method, which uses Steiger's test to test the difference between the Pearson correlations of 204 genetic variants with both the exposure and outcome [39].

205

206 Multivariable MR analysis of WBC counts on CRC risk

The IVW method was used for the MVMR analysis. First, a pair-wise analysis between allfive WBC subtype counts was undertaken, where the proportion of variance explained (PVE)

209 for SNPs used to instrument a WBC trait was estimated in the other four WBC subtypes 210 using previously described methodology [45]. The direct effect of each WBC subtype was 211 estimated by adding in all five WBC subtypes into the MVMR model. Bias arising from 212 weak instruments was also determined here. This was undertaken using methodology 213 described by Sanderson et al., where a generalized version of Cochran's Q was employed to 214 evaluate instrument strength [52]. Standard Cochran's Q statistic [47] was calculated to 215 detect the presence of heterogeneity. For those traits with an F-statistic <10, a follow-up 216 MVMR analysis was done accounting for the presence of weak instruments.

217

218 UK Biobank phenotypic data

219 Between the years of 2007 and 2010, UKBB participants visited assessment centres (N=22) 220 throughout the UK [53,54]. The individuals had their health records linked, their genomes 221 sequenced, and underwent multiple evaluations, such as self-report questionnaires and 222 medical examinations [53,54]. The latter includes the analysis of blood cell samples using 223 Beckman Coulter LH750 instruments designed for high throughput screening [55]. Total 224 WBC count and WBC subtype percentage (%) were measured, with absolute WBC subtype 225 count derived as "WBC subtype % / 100 x total WBC" and expressed as 10^9 cells/Litre [55]. 226 The blood sampling date variable was split into year, month, day, and minutes (passed since 227 the start of the day of the appointment visit). Additional variables were gathered including 228 recruitment centre, sampling device ID, age, genetic sex, principal components 1 to 10, BMI, 229 Townsend deprivation index, smoking and alcohol drinker status (self-report questionnaire – 230 UKBB codes 20116 and 20117). CRC cases were identified through hospital inpatient records coded to the 10th version of the International Classification of Disease (ICD-10). 231

232

233 Filtering and selection criteria

234 The UKBB dataset underwent a series of steps prior to further analyses. Withdrawn 235 participants and those of non-European ancestry were excluded. Viable controls and incident 236 CRC cases were defined using methodology previously described by Burrows et al. [56] 237 (Supplementary Table 4). Here, we defined incident CRC cases as those diagnosed at least 238 one year after blood sampling. Participants with no WBC measurement data or sampling date 239 were removed, as were those who were known to be pregnant, have chronic conditions (e.g. 240 HIV, blood cancers, thalassaemia), or undergoing erythropoietin treatment, as in Astle et al. 241 [57] and Chen et al. [32], given the effects of these traits on WBC measurements. Those with 242 acute conditions (e.g. upper respiratory infections) diagnosed less than 3 months prior to 243 blood sampling were excluded. Finally, missing values in "Townsend Deprivation Index", 244 "Body mass index", "Smoking status" and "Alcohol drinker status" variables were removed.

245

246 Cohort study between WBC count and CRC

247 We conducted a cohort analysis between circulating WBCs and incident CRC. WBC count 248 values were log-transformed, after which they were adjusted for the following covariates: assessment centre, sex, age, age², PCs 1 to 10, as in the Chen et al. GWAS [32]. The resulting 249 250 residuals were rank-inverse normal transformed and then used in a logistic regression on 251 CRC incidence. This main observational analysis was termed "Model 1", a minimally 252 adjusted model. An additional fully adjusted analysis was undertaken, termed "Model 2", 253 where BMI, Townsend DI, smoker status and alcohol drinker status were added as additional 254 covariates. Following this, another pair of analyses was run, where all five WBC subtype 255 counts were added together into the model to reduce potential bias due to their correlated 256 values. Analyses where each WBC trait was studied individually were termed as 257 "univariable", while those where they were added together were termed as "multivariable".

258	2	5	8
-----	---	---	---

259 Working environment

All analyses were performed with R version 4.1.2 (Bird Hippie) in a Linux environment supported by the University of Bristol's Advanced Computing Research Centre (ACRC). Genetic data preparation, as well as the MR analyses, were undertaken with the "TwoSampleMR" R package [38,39]. The MVMR analyses were undertaken with the "MVMR" R package [58]. Scripts associated with this study are available on GitHub: <u>https://github.com/andrewcon/wbc-crc</u>.

266

267 **Results**

268

269 Effect of WBC count on CRC

Before performing the MR analysis, the average F-statistic for each WBC trait was estimated
to detect the presence of weak instrument bias, which is generally indicated by an average Fstatistic < 10 [44]. For overall CRC, these were 64.48 (basophil count, 171 SNPs), 124.72
(eosinophil count, 396 SNPs), 105.85 (lymphocyte count, 444 SNPs), 147.44 (monocyte
count, 477 SNPs), 98.84 (neutrophil count, 387 SNPs), indicating strong MR instruments
(Supplementary Table 5).

276

The IVW method showed evidence of a protective effect of basophil count (1-SD increase in WBC count OR: 0.88, 95% CI: 0.78-0.99, P-value: 0.037) for CRC risk (Figure 2, Supplementary Figure 1). For eosinophil count, the IVW method showed evidence of a protective effect for CRC risk (OR: 0.93, 95% CI: 0.88-0.98, P-value: 0.012) (Figure 2, Supplementary Figure 1). These results were confirmed by the MR-Egger, weighted median and MR-PRESSO sensitivity methods (Supplementary Table 6). The IVW method

also showed a protective effect of eosinophil count for CRC risk (OR: 0.91, 95% CI: 0.850.99, P-value: 0.021) in females. All results, including those for sex- and site-specific CRC,
are available in Supplementary Table 6.

286

287 In site specific CRC analyses, the univariable IVW method demonstrated evidence for a 288 protective effect of basophil count on colon (OR: 0.85, 95% CI: 0.74-0.98, P-value: 0.022) 289 and distal colon (OR: 0.82, 95% CI: 0.70-0.97, P-value: 0.019) cancer (Supplementary 290 **Table 6**). For eosinophil count, the main IVW analysis provided evidence for a protective 291 effect for colon (OR: 0.90, 95% CI: 0.84-0.96, P-value: 0.001), proximal colon (OR: 0.89, 292 95% CI: 0.82-0.96, P-value: 0.003) and distal colon (OR: 0.89, 95% CI: 0.82-0.97, P-value: 293 0.007) cancer (**Supplementary Table 6**). These results were mostly supported by sensitivity 294 analyses. There was a protective effect of total WBC count on colon (OR: 0.91, 95% CI: 295 0.85-0.99, P-value: 0.02) and proximal colon (OR: 0.90, 95% CI: 0.82-0.98, P-value: 0.015) 296 cancer (Supplementary Table 6).

297

298 Next, the presence of vertical and horizontal pleiotropy in the MR analyses was analysed. 299 Cochran's heterogeneity test indicated the presence of heterogeneity in all but one WBC trait-300 CRC pair (basophil count-male CRC, P_{HET}=0.104) (Supplementary Table 7). Following 301 this, the MR-Egger test for horizontal pleiotropy was performed. Here, evidence for this type 302 of pleiotropy was identified for eosinophil count and colon ($P_{PLT}=0.018$), distal colon 303 (P_{PLT}=0.015), female (P_{PLT}=0.049), male (P_{PLT}=0.041) and overall (P_{PLT}=0.015) CRC risk, 304 suggesting a possible bias of MR estimates. This was also the case for lymphocyte count in 305 female CRC (P_{PLT}=0.016) (Supplementary Table 7). Although the MR-PRESSO method 306 identified the presence of SNP horizontal-pleiotropic outliers, there was little evidence that

307 the removal of these outliers contributed to a notable shift in the point estimates308 (Supplementary Table 8).

309

310 Multivariable MR of WBC count on CRC

311 A pair-wise analysis of the proportion of variance explained (PVE) for SNPs instrumenting 312 each WBC trait indicated a low PVE for each of the other WBC traits, with the exception of 313 basophil count (2.44% vs. 2.39% when instrumenting neutrophil count) (Supplementary 314 **Table 9**). The overall results indicated that statistical power should not suffer to a large 315 degree by adding all five WBC subtype counts into the MVMR analysis. Here, the MVMR 316 IVW method estimated a protective effect of eosinophil count (OR: 0.88, 95% CI: 0.80-0.97, 317 P-value: 0.011) and lymphocyte count (OR: 0.84, 95% CI: 0.76-0.93, P-value: 0.0007) on 318 CRC risk (Figure 2). Regarding sex-specific estimates, eosinophil count was protective for 319 CRC risk (OR: 0.83, 95% CI: 0.73-0.94, P-value: 0.004) in females, this was also the case for 320 lymphocyte count (OR: 0.76, 95% CI: 0.67-0.87, P-value: 6.46E-05).

321

Eosinophil count was estimated to have a direct protective effect on colon (OR: 0.84, 95% CI: 0.75-0.94, P-value: 0.002), proximal colon (OR: 0.92, 95% CI: 0.85-1.00, P-value: 0.042) and distal colon (OR: 0.88, 95% CI: 0.74-1.00, P-value: 0.049) cancer (**Supplementary Table 10**). Lymphocyte count was estimated to have a direct protective effect on colon (OR: 0.85, 95% CI: 0.76-0.96, P-value: 0.007), distal colon (OR: 0.77, 95% CI: 0.67-0.88, P-value: 0.0001) and rectal (OR: 0.86, 95% CI: 0.75-0.98, P-value: 0.022) cancer anatomical subsites (**Supplementary Table 10**).

329

330 Sensitivity analyses were undertaken to assess heterogeneity and the presence of weak 331 instruments in the MVMR analysis. There was evidence of heterogeneity in all WBC trait-

332 CRC pairs (**Supplementary Table 11**). Conditional F-statistics showed evidence of weak 333 instruments (F<10) for basophil count (**Supplementary Table 11**). Based on these results, an 334 additional MVMR analysis was run adjusting for weak instruments for basophil count 335 (overall CRC OR_{Weak} : 1.3; male CRC OR_{Weak} : 1.2; female CRC OR_{Weak} : 1.7; colon cancer 336 OR_{Weak} : 1.5; proximal colon cancer OR_{Weak} : 1.5; distal colon cancer OR_{Weak} : 1.5; rectal 337 cancer OR_{Weak} : 1.6) on CRC risk (**Supplementary Table 11**).

338

339 Cohort observational analysis between WBC count and CRC

340 336,816 UKBB participants remained after passing filtering and selection criteria 341 (Supplementary Figure 2). Of these, 332,773 were controls and 4,043 were incident CRC 342 cases. When split by genetic sex, there were 154,629 male and 178,144 female controls and 343 2,316 male and 1,727 female cases. Those with CRC were more likely to be male (57% vs. 344 46%), had a higher average age (60.7 vs. 55.8 years), slightly higher BMI (28.0 vs. 27.4 345 kg/m²) and were more likely to have been cigarette smokers in the past (46% vs. 55% never 346 smokers and 44% vs. 34% pervious smokers) (Table 1).

Characteristic	Control , N = 332,773 ¹	Case, N = 4,043 ¹
Sex		
Female	178,144 / 332,773 (54%)	1,727 / 4,043 (43%)
Male	154,629 / 332,773 (46%)	2,316 / 4,043 (57%)
Age (years)	55.8 (8.1)	60.7 (6.6)
Body mass index	27.4 (4.7)	28.0 (4.7)
Smoking status		
Never	183,987 / 332,773 (55%)	1,861 / 4,043 (46%)
Previous	114,349 / 332,773 (34%)	1,790 / 4,043 (44%)
Current	34,437 / 332,773 (10%)	392 / 4,043 (9.7%)
Alcohol drinker status		
Never	10,655 / 332,773 (3.2%)	122 / 4,043 (3.0%)
Previous	10,982 / 332,773 (3.3%)	140 / 4,043 (3.5%)
Current	311,136 / 332,773 (93%)	3,781 / 4,043 (94%)
Townsend deprivation index	-1.4 (3.0)	-1.6 (3.0)

Basophil count	0.0 (0.1)	0.0 (0.1)
Eosinophil count	0.2 (0.1)	0.2 (0.1)
Lymphocyte count	1.9 (0.6)	1.9 (0.6)
Monocyte count	0.5 (0.2)	0.5 (0.2)
Neutrophil count	4.2 (1.4)	4.3 (1.4)
Overall WBC count	6.9 (1.7)	7.0 (1.8)
1n / N (%); Mean (SD)		

348	Table 1. Baseline characteristics of UK Biobank study sample.
-----	---

349

350 As a percentage of the total WBC count based on the median values, basophils accounted for 351 0.3%, eosinophils 2.11%, lymphocytes 28.16%, monocytes 6.78%, and neutrophils 60.39% 352 (Supplementary Table 12). A pair-wise correlation matrix between each WBC subtype 353 showed a high correlation between total WBC and neutrophil count, while for the other 354 subtypes the correlation coefficients were equal or below 0.3 (Supplementary Figure 3). 355 Batch variables (e.g. blood sample device and sampling date), Townsend DI, and alcohol 356 drinker status explained some of the variance in WBC count (0% to 0.66%). Depending on 357 the WBC subtype, genetic sex explained between 0.23% to 2.93% of the variance, BMI 358 explained between 0.14% to 2.64%, and smoking status explained between 0.44% to 3.85% 359 (Supplementary Figure 4).

360

In the main analysis ("Model 1" - the minimally adjusted model), basophil count was positively associated with CRC risk (RR: 1.06, 95% CI: 1.02-1.09, P-value: 0.0005), as was monocyte (RR: 1.05, 95% CI: 1.02-1.08, P-value: 0.003) and neutrophil count (RR: 1.09, 95% CI: 1.06-1.13, P-value: 1.94E-08) (**Figure 2, Supplementary Table 13**). In "Model 2", eosinophil count was negatively associated with CRC risk (overall CRC RR: 0.96, 95% CI: 0.93-0.99, P-value: 0.022) (**Supplementary Table 13**).

368	Observational associations were re-computed by adding all five WBC subtype counts
369	together. In the minimally adjusted "Model 1", eosinophil count (RR: 0.96, 95% CI: 0.93-
370	0.99, P-value: 0.009) was associated with lower overall CRC odds, while basophil (RR: 1.04,
371	95% CI: 1.01-1.08, P-value: 0.008) and neutrophil count (RR: 1.08, 95% CI: 1.05-1.12, P-
372	value: 1.92E-06) were associated with an increase in overall CRC risk (Supplementary
373	Table 14). These results largely coincided with those from the fully adjusted "Model 2"
374	analyses (Supplementary Table 14). All results, including those for sex-specific CRC, are
375	available in Supplementary Table 14.





Figure 2. The relationship between WBC count and CRC risk based on UV, MV twosample MR and cohort observational analyses. Each WBC trait is presented on the X-axis. The estimated effect is presented on the Y-axis. Point estimates were filled where the P-value was less than 0.05. Results are interpreted as ORs (95% CI) for CRC risk per 1-SD normalized increment in WBC count.

383

384 **Discussion**

In this study we aimed to estimate the effects of five circulating WBC subtypes on CRC risk by using a combined genetic epidemiologic and longitudinal cohort framework. Through the aid of MVMR, we were able to assess the independent causal effect of WBC counts by adjusting for their shared genetic architecture. Taken together, the evidence across analyses suggests a potential protective effect of increased circulating eosinophil and lymphocyte count on CRC risk.

391

Consistent with our study, Prizment et al found that eosinophil count (tertiles Q3 and Q2 vs. Q1) was negatively associated with odds of developing colon, but not of rectal cancer [19]. Similar results have been reported for other cancers; Wong et al. reported a negative trend between increasing eosinophil count quartiles and lung adenocarcinoma odds in a UKBB study [59], while a similar study looking at prostate cancer showed a negative association between eosinophil count quintiles Q3-5, as well as a per 1-SD increase in the trait (HR 0.96 vs. OR 0.93 for CRC in our analysis) [60].

399

Eosinophils have a well-established role in allergic disease, including asthma and allergic rhinitis [61]. Indeed, MR analyses have also reported a causal effect of eosinophil count on allergic disease [57,62] and a recent systematic review investigating the relationship between allergies and cancer reported evidence for a reduced risk of CRC in those with allergic diseases [63].

405

406 Here, our results suggest that the immune response through by eosinophils provides407 protection against tumour development. Indeed, in several neoplasia, including CRC,

408 eosinophils have been found to play an anti-tumourigenic role and are a source of anti-409 tumourigenic molecules, such as eosinophil-derived neurotoxin (EDN) [64,65]. Experimental 410 studies have also found a tumour-protective effect of IgE [66]. Increased eosinophil 411 recruitment to the CRC tumour site has also been associated with better survival, even when 412 adjusting for the effects of CD8⁺ T-cells [13], and eosinophil-specific granule secretion of 413 granzyme A has been linked with the killing of CRC cells [67].

414

415 In addition to eosinophil count, we also found a protective effect of lymphocyte count on 416 CRC risk. While this was not apparent in the MR analysis, the MVMR estimates indicated 417 lower ORs for CRC across all anatomical subsites (proximal colon cancer trended towards 418 protective) with increased lymphocyte counts. The multivariable fully adjusted "Model 2" in 419 the cohort analysis also indicated that there could be a negative association with CRC risk. It 420 is not surprising that we found a protective effect of higher circulating levels of lymphocytes 421 with CRC odds given their established role in combatting tumour development [68]. Tumour-422 infiltrating lymphocytes (TILs) like CD8+ T-cells help antagonise tumour growth through 423 direct action and recruitment of other immune cells [68]. High levels of TILs were previously 424 associated with better CRC overall survival and disease-free survival [22,68]. In support of 425 our findings, two observational studies found higher lymphocyte counts compared to cases 426 vs. controls a year to six months prior to CRC diagnosis [69,70]. However, these results 427 could indicate production and recruitment of lymphocytes to the site of pre-cancerous or 428 undetected tumours rather than a causal effect.

429

430 Limitations

There are several limitations to this study. With regards to the cohort analysis, only baselineblood measurements were available. This assumes that WBC counts were constant and did

not allow us to establish a relationship between a trend in WBC count and its relationship with CRC odds. Nevertheless, baseline WBC count measurements have previously been shown to be associated with disease risk [59,60,71,72], making their study in relation to disease development a worthwhile endeavour. Also, in the cohort analysis, incident CRC cases were defined as those diagnosed at least one year after blood sampling, in order to not diminish the number of cases to a large degree. However, as CRC develops over a long period, our cohort analysis may have not excluded all participants with undiagnosed CRC.

440

441 With regards to the MR analysis, the genetic instruments used here proxied for lifetime 442 variation of WBC count. Therefore, the MR analysis cannot be used to infer how large 443 changes over a short timespan might affect CRC development. Regarding the MVMR 444 method, caution should be applied when investigating traits with very weak instruments, as it 445 cannot reliably adjust for those traits [58]. This was the case for basophil count, as the F-446 statistic was estimated to be between 4.7 and 4.8 (Supplementary Table 12). Therefore, 447 despite pointing to an increased detrimental effect compared to the main MVMR analysis, 448 ORs derived from the weak-MVMR analysis should be interpreted with this in mind.

449

450 Conclusion

In summary, the results generated here provide evidence for a protective causal effect of elevated levels of circulating eosinophil and lymphocyte counts on CRC risk. Going forward, additional research is needed to disentangle the biological mechanisms and pinpoint specific pathways through which eosinophils and lymphocytes might protect against CRC development.

457 Availability of data and materials

458 Summary statistics for WBC counts were downloaded from the following website: 459 http://www.mhi-humangenetics.org/en/resources/. The summary-level GWAS data on 460 outcomes used in this study were made available following an application to the Genetics and 461 Epidemiology of Colorectal Cancer Consortium (GECCO): 462 https://www.fredhutch.org/en/research/divisions/public-health-sciencesdivision/research/cancer-prevention/genetics-epidemiology-colorectal-cancer-consortium-463

- 464 gecco.html.
- 465

466 **Contributions**

467 AC, CJB, JH and EEV conceived the idea for the paper. AC conducted the analysis. All 468 authors contributed to the interpretation of the findings. AC, CJB and EEV wrote the 469 manuscript. All authors critically revised the paper for intellectual content and approved the 470 final version of the manuscript.

471

472 Funding information

473 AC acknowledges funding from grant MR/N0137941/1 for the GW4 BIOMED MRC DTP, 474 awarded to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research 475 Council (MRC)/UKRI. NJT is the PI of the Avon Longitudinal Study of Parents and Children 476 (Medical Research Council & Wellcome Trust 217065/Z/19/Z) and is supported by the University of Bristol NIHR Biomedical Research Centre (BRC-1215-2001). NJT 477 478 acknowledges funding from the Wellcome Trust (202802/Z/16/Z). EEV, CJB, ND and NJT 479 acknowledge funding by the CRUK Integrative Cancer Epidemiology Programme 480 (C18281/A29019). NJT, EEV and CJB work in a unit funded by the UK Medical Research 481 Council (MC_UU_00011/1 & MC_UU_00011/4) and the University of Bristol. EEV and 482 CJB are supported by Diabetes UK (17/0005587) and the World Cancer Research Fund 483 (WCRF UK), as part of the World Cancer Research Fund International grant program 484 (IIG_2019_2009). JRH acknowledges funding by the National Cancer Institute at the U.S. 485 National Institutes of Health (R21CA230486). This work was also supported by the Elizabeth 486 Blackwell Institute for Health Research, University of Bristol, and the Wellcome Trust 487 Institutional Strategic Support Fund (ISSF 204813/Z/16/Z). The funders of the study had no 488 role in the study design, data collection, data analysis, data interpretation or writing of the 489 report.

490

491 Ethics declaration

492 All participants provided written informed consent, and each study was approved by the 493 relevant research ethics committee or institutional review board.

101	
494	

495 **Consent for publication**

496 All authors consented to the publication of this work.

497

498 **Competing interests**

499 The authors declare no competing interests.

500

- 501 Supplementary information
- 502 Additional file 1
- 503 Supplementary Figures.
- 504 Additional file 2
- 505 Supplementary Tables.
- 506 Additional file 3
- 507 STROBE-MR checklist.
- 508 Additional file 4
- 509 STROBE Cohort checklist.
- 510 Additional file 5
- 511 Full funding and acknowledgements details.
- 512

513 **References**

514	[1]	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer
515		statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36
516		cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
517		https://doi.org/10.3322/CAAC.21492.
518	[2]	Sung H, Siegel RL, Rosenberg PS, Jemal A. Emerging cancer trends among young
519		adults in the USA: analysis of a population-based cancer registry. Lancet Public Heal
520		2019;4:e137-47. https://doi.org/10.1016/S2468-2667(18)30267-
521		6/ATTACHMENT/EA91DB97-1C30-4C2F-B604-48BF68319153/MMC1.PDF.
522	[3]	Mauri G, Sartore-Bianchi A, Russo AG, Marsoni S, Bardelli A, Siena S. Early onset
523		colorectal cancer in young individuals. Mol Oncol 2019;13:109.
524		https://doi.org/10.1002/1878-0261.12417.
525	[4]	Xi Y, Xu P. Global colorectal cancer burden in 2020 and projections to 2040. Transl
526		Oncol 2021;14:101174. https://doi.org/10.1016/J.TRANON.2021.101174.
527	[5]	Chambers AC, Dixon SW, White P, Williams AC, Thomas MG, Messenger DE.
528		Demographic trends in the incidence of young onset colorectal cancer: a
529		population D based study. Br J Surg 2020;107:595. https://doi.org/10.1002/BJS.11486.

530	[6]	SEER. Surveillance, Epidemiology, and End Results (SEER) Program. 2019.
531	[7]	Araghi M, Soerjomataram I, Bardot A, Ferlay J, Cabasag CJ, Morrison DS, et al.
532		Changes in colorectal cancer incidence in seven high-income countries: a population-
533		based study. Lancet Gastroenterol Hepatol 2019;4:511–8.
534		https://doi.org/10.1016/S2468-1253(19)30147-5.
535	[8]	Hull MA. Nutritional prevention of colorectal cancer. Proc Nutr Soc 2021;80:59–64.
536		https://doi.org/10.1017/S0029665120000051.
537	[9]	Nicholson LB. The immune system. Essays Biochem 2016;60:275–301.
538		https://doi.org/10.1042/EBC20160017.
539	[10]	Lee YJ, Lee HR, Nam CM, Hwang UK, Jee SH. White Blood Cell Count and the Risk
540		of Colon Cancer. Yonsei Med J 2006;47.
541	[11]	Wu J, Ge X, Zhu W, Zhi Q, Xu M, Duan W, et al. Values of applying white blood cell
542		counts in the prognostic evaluation of resectable colorectal cancer. Mol Med Rep
543		2019;19:2330-40. https://doi.org/10.3892/MMR.2019.9844.
544	[12]	Watt DG, Martin JC, Park JH, Horgan PG, McMillan DC. Neutrophil count is the most
545		important prognostic component of the differential white cell count in patients
546		undergoing elective surgery for colorectal cancer 2015;210:24-30.
547	[13]	Prizment AE, Vierkant RA, Smyrk TC, Tillmans LS, Lee JJ, Sriramarao P, et al.
548		Tumor eosinophil infiltration and improved survival of colorectal cancer patients: Iowa
549		Women's Health Study. Mod Pathol 2016;29:516–27.
550		https://doi.org/10.1038/modpathol.2016.42.
551	[14]	Rosman Y, Hornik-Lurie T, Meir-Shafrir K, Lachover-Roth I, Cohen-Engler A,
552		Munitz A, et al. Changes in peripheral blood eosinophils may predict colorectal cancer
553		 A retrospective study. World Allergy Organ J 2022;15:100696.
554		https://doi.org/10.1016/J.WAOJOU.2022.100696.
555	[15]	Iijima K, Fujibayashi K, Okumura M, Sasabe N, Gunji T. Number of Eosinophils and
556		Incidence of Cancer in a Japanese Population : A Single Institution Study. Orig Artic
557	54.63	Ningen Dock Int 2019;6:56–61.
558	[16]	Liu Q, Luo D, Cai S, Li Q, Li X. Circulating basophil count as a prognostic marker of
559		tumor aggressiveness and survival outcomes in colorectal cancer. Clin Transl Med
560	F 1 77 1	2020 91 2020;9:1–12. https://doi.org/10.1186/S40169-019-0255-4.
561	[1/]	wei Y, Zhang X, wang G, Zhou Y, Luo M, wang S, et al. The impacts of
562		pretreatment circulating eosinophils and basophils on prognosis of stage $\Box - \Box$
563		colorectal cancer. Asia Pac J Clin Oncol 2018;14:e243–51. https://doi.org/10.1111/AJCO.12971
564	F191	Hups://doi.org/10.1111/AJCO.120/1.
505	[10]	Deritumoral assingphils predict regurrence in coloractal aspect. Mod Dathel 2015 282
500		2014:28:403 13 https://doi.org/10.1038/modpathol.2014.104
507	[10]	Drizment AE Anderson KE Visuanathan K Folsom AD Inverse association of
500	[19]	eosinophil count with colorectal cancer incidence: Atherosclerosis Risk in
570		Communities study Cancer Enidemiol Biomarkers Prev 2011:20:1861_4
570		https://doi.org/10.1158/1055-9965 EPI-11-0360/66619/AM/INVERSE-
572		ASSOCIATION-OF-FOSINOPHIL-COUNT-WITH
573	[20]	Ma W Yang L Li P Lu X Cai L Association between allergic conditions and
574	[20]	colorectal cancer risk/mortality: a meta-analysis of prospective studies. Sci Reports
575		2017 71 2017.7.1–7 https://doi.org/10.1038/s41598-017-04772-9
576	[21]	Yamamoto T. Kawada K. Obama K. Inflammation-Related Biomarkers for the
577	[]	Prediction of Prognosis in Colorectal Cancer Patients Int J Mol Sci 2021 Vol 22
578		Page 8002 2021:22:8002. https://doi.org/10.3390/IJMS22158002.
579	[22]	Tanio A, Saito H, Uejima C, Takaya S, Yamamoto M, Tokuvasu N. et al. A prognostic
	с л	, , , , , , , , , , , , , , , , , , ,

580 581		index for colorectal cancer based on preoperative absolute lymphocyte, monocyte, and neutrophil counts. Surg Today 2019;49:245–53. https://doi.org/10.1007/S00595-018-
582		1728-6/TABLES/2.
583	[23]	Olingy CE, Dinh HQ, Hedrick CC. Monocyte heterogeneity and functions in cancer. J
584		Leukoc Biol 2019;106:309–22. https://doi.org/10.1002/JLB.4RI0818-311R.
585	[24]	Quail DF, Amulic B, Aziz M, Barnes BJ, Eruslanov E, Fridlender ZG, et al.
586		Neutrophil phenotypes and functions in cancer: A consensus statement. J Exp Med
587		2022;219:39. https://doi.org/10.1084/JEM.20220011/213202.
588 589	[25]	Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet 2014;23:R89–98.
590		https://doi.org/10.1093/hmg/ddu328.
591	[26]	Zheng J, Baird D, Borges M-C, Bowden J, Hemani G, Haycock P, et al. Recent
592	L - J	Developments in Mendelian Randomization Studies, Curr Epidemiol Reports
593		2017·4·330–45 https://doi.org/10.1007/s40471-017-0128-6
594	[27]	Smith GD Ebrahim S SEER Surveillance Epidemiology and End Results (SEER)
595	[=,]	Program Int I Epidemiol 2003:32:1–22 https://doi.org/10.1093/ije/dvg070
596	[28]	Smith GD Ebrahim S Mendelian randomization: prospects notentials and
597	[20]	limitations Int I Epidemiol 2004:33:30–42 https://doi.org/10.1093/ije/dyh132
598	[29]	Davies NM Holmes M V Davey Smith G Reading Mendelian randomisation
599	[27]	studies: a guide glossary and checklist for clinicians BMI 2018:362:601
600		https://doi.org/10.1136/hmi.k601
601	[30]	Carter AR Sanderson F. Hammerton G. Richmond RC. Davey Smith G. Heron L. et
602	[30]	al Mendelian randomisation for mediation analysis: current methods and challenges
603		for implementation Fur I Epidemiol 2021 365 2021:36:465–78
604		https://doi.org/10.1007/S10654-021-00757-1
605	[31]	Skrivankova VW Richmond RC Woolf BAR Davies NM Swanson SA
606	[91]	Vanderweele TI et al Strengthening the reporting of observational studies in
607		epidemiology using mendelian randomisation (STROBE-MR): explanation and
608		elaboration, BMJ 2021:375, https://doi.org/10.1136/BMJ.N2233.
609	[32]	Chen MH Raffield LM Mousas A Sakaue S Huffman IE Moscati A et al Trans-
610	[]	ethnic and Ancestry-Specific Blood-Cell Genetics in 746.667 Individuals from 5
611		Global Populations, Cell 2020:182:1198-1213.e14.
612		https://doi.org/10.1016/i.cell.2020.06.045.
613	[33]	Huyohe IR Bien SA Harrison TA Kang HM Chen S Schmit SL et al Discovery of
614	[35]	common and rare genetic risk variants for colorectal cancer. Nat Genet 2019:51:76
615		https://doi.org/10.1038/S41588-018-0286-6.
616	[34]	Peters U. Jiao S. Schumacher FR. Hutter CM. Aragaki AK. Baron JA. et al.
617	[]	Identification of Genetic Susceptibility Loci for Colorectal Tumors in aGenome-Wide
618		Meta-analysis, Gastroenterology 2013:144.
619		https://doi.org/10.1053/i.gastro.2012.12.020.
620	[35]	Schumacher FR, Schmit SL, Jiao S, Edlund CK, Wang H, Zhang B, et al. Genome-
621	[]	wide association study of colorectal cancer identifies six new susceptibility loci. Nat
622		Commun 2015 61 2015:6:1–7. https://doi.org/10.1038/ncomms8138.
623	[36]	Schmit SL, Edlund CK, Schumacher FR, Gong J, Harrison TA, Huyghe JR, et al.
624		Novel Common Genetic Susceptibility Loci for Colorectal Cancer, JNCI J Natl Cancer
625		Inst 2019;111:146–57. https://doi.org/10.1093/JNCI/DJY099.
626	[37]	Zhang B, Jia WH, Matsuda K, Kweon SS, Matsuo K, Xiang YB, et al. Large-scale
627		genetic study in East Asians identifies six new loci associated with colorectal cancer
628		risk. Nat Genet 2014;46:533. https://doi.org/10.1038/NG.2985.
629	[38]	Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-base

630		platform supports systematic causal inference across the human phenome. Elife
631		2018;7.
632	[39]	Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between
633		imprecisely measured traits using GWAS summary data. PLoS Genet 2017;13.
634		https://doi.org/10.1371/JOURNAL.PGEN.1007081.
635	[40]	Haycock PC, Burgess S, Wade KH, Bowden J, Relton C, Davey Smith G. Best (but
636		oft-forgotten) practices: the design, analysis, and interpretation of Mendelian
637		randomization studies. Am J Clin Nutr 2016;103:965–78.
638		https://doi.org/10.3945/ajcn.115.118216.
639	[41]	Auton A, Abecasis GR, Altshuler DM, Durbin RM, Bentley DR, Chakravarti A, et al.
640		A global reference for human genetic variation. Nature 2015;526:68–74.
641		https://doi.org/10.1038/nature15393.
642	[42]	Wootton RE, Sallis HM. Let's call it the effect allele: a suggestion for GWAS naming
643		conventions. Int J Epidemiol 2020;49:1734–5. https://doi.org/10.1093/IJE/DYAA149.
644	[43]	Burgess S, Dudbridge F, Thompson SG. Combining information on multiple
645		instrumental variables in Mendelian randomization: comparison of allele score and
646		summarized data methods. Stat Med 2016;35:1880–906.
647		https://doi.org/https://doi.org/10.1002/sim.6835.
648	[44]	Burgess S, Thompson SG. Bias in causal estimates from Mendelian randomization
649		studies with weak instruments. 2010.
650	[45]	Shim H, Chasman DI, Smith JD, Mora S, Ridker PM, Nickerson DA, et al. A
651		Multivariate Genome-Wide Association Analysis of 10 LDL Subfractions, and Their
652		Response to Statin Treatment, in 1868 Caucasians. PLoS One 2015;10:120758.
653		https://doi.org/10.1371/JOURNAL.PONE.0120758.
654	[46]	Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al.
655		Guidelines for performing Mendelian randomization investigations. Wellcome Open
656		Res 2020 4186 2020;4:186. https://doi.org/10.12688/wellcomeopenres.15555.2.
657	[47]	Greco M F Del, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in
658		Mendelian randomisation studies with summary data and a continuous outcome. Stat
659		Med 2015;34:2926–40. https://doi.org/10.1002/SIM.6522.
660	[48]	Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid
661		instruments: effect estimation and bias detection through Egger regression. Int J
662		Epidemiol 2015;44:512–25. https://doi.org/10.1093/ije/dyv080.
663	[49]	Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in
664		Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
665		Estimator. Genet Epidemiol 2016;40:304–14.
666		https://doi.org/https://doi.org/10.1002/gepi.21965.
667	[50]	Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian
668		randomization via the zero modal pleiotropy assumption. Int J Epidemiol
669		2017;46:1985–98. https://doi.org/10.1093/ije/dyx102.
670	[51]	Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy
671		in causal relationships inferred from Mendelian randomization between complex traits
672		and diseases. Nat Genet 2018 505 2018;50:693-8. https://doi.org/10.1038/s41588-018-
673		0099-7.
674	[52]	Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of
675		multivariable Mendelian randomization in the single-sample and two-sample summary
676		data settings. Int J Epidemiol 2019;48:713–27. https://doi.org/10.1093/ije/dyy262.
677	[53]	Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an
678		open access resource for identifying the causes of a wide range of complex diseases of
679		middle and old age. PLoS Med 2015;12:e1001779–e1001779.

680		https://doi.org/10.1371/journal.pmed.1001779.
681	[54]	Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK
682		Biobank resource with deep phenotyping and genomic data. Nature 2018;562:203–9.
683		https://doi.org/10.1038/s41586-018-0579-z.
684	[55]	Simon Sheard Rob Nicholls James Froggatt AM. UK Biobank Haematology Data
685		Companion Document n.d.
686	[56]	Burrows K, Bull CJ, Dudding T, Gormley M, Robinson T, Tan V, et al. Genome-wide
687		Association Study of Cancer Risk in UK Biobank 2021.
688		https://doi.org/10.5523/bris.aed0u12w0ede20olb0m77p4b9.
689	[57]	Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, et al. The Allelic
690		Landscape of Human Blood Cell Trait Variation and Links to Common Complex
691		Disease. Cell 2016;167:1415-1429.e19. https://doi.org/10.1016/j.cell.2016.10.042.
692	[58]	Sanderson E, Spiller W, Bowden J. Testing and correcting for weak and pleiotropic
693		instruments in two-sample multivariable Mendelian randomization. Stat Med
694		2021;40:5434-52. https://doi.org/10.1002/SIM.9133.
695	[59]	Wong JYY, Bassig BA, Loftfield E, Hu W, Freedman ND, Ji BT, et al. White Blood
696		Cell Count and Risk of Incident Lung Cancer in the UK Biobank. JNCI Cancer Spectr
697		2020;4. https://doi.org/10.1093/JNCICS/PKZ102.
698	[60]	Watts EL, Perez-Cornago A, Kothari J, Allen NE, Travis RC, Key TJ. Hematologic
699		markers and prostate cancer risk: a prospective analysis in UK Biobank. Cancer
700		Epidemiol Biomarkers Prev 2020;29:1615–26. https://doi.org/10.1158/1055-9965.EPI-
701		19-1525/70795/AM/HAEMATOLOGICAL-MARKERS-AND-PROSTATE-
702		CANCER-RISK-A.
703	[61]	Benson VS, Hartl S, Barnes N, Galwey N, Van Dyke MK, Kwon N. Blood eosinophil
704		counts in the general population and airways disease: a comprehensive review and
705		meta-analysis. Eur Respir J 2022;59. https://doi.org/10.1183/13993003.04590-2020.
706	[62]	Morrison J, Knoblauch N, Marcus JH, Stephens M, He X. Mendelian randomization
707		accounting for correlated and uncorrelated pleiotropic effects using genome-wide
708		summary statistics. Nat Genet 2020 527 2020;52:740–7.
709	[(0]	https://doi.org/10.1038/s41588-020-0631-4.
710	[63]	Karim AF, Westenberg LEH, Eurelings LEM, Otten R, Gerth Van Wijk R. The
/11		association between allergic diseases and cancer: a systematic review of the literature
/12	5643	
/13	[64]	Varricchi G, Galdiero MR, Loffredo S, Lucarini V, Marone GG, Matter F, et al.
714		Eosinophils: The unsung heroes in cancer? vol. 7. 2018.
715	[65]	https://doi.org/10.1080/2102402A.2017.1393134.
710	[03]	Arnold IC, Artola-Boran M, Gurtner A, Bertram K, Bauer M, Frangez Z, et al. The
717		GM-CSF-IRF5 signaling axis in cosmophils promotes antitumor inimumity through
/18		activation of type 1 1 cell responses. J Exp Med 2020;217.
719	[66]	Illups.//doi.org/10.1064/JEM1.20190/00/15211/. Diotzar D. Elnak K.C. Cramasao V. Dakar K. Stout MM. Sabultz C. at al. IaE/EacDI
720	[00]	ratizer D, Elpek KO, Clemasco V, Daker K, Stout Wivi, Schultz C, et al. IgE/FCeKI-
721		responses. Coll Pop 2015:10:1427 https://doi.org/10.1016/J.CEL.PED 2015.02.015
722	[67]	Legrand E. Driss V. Delbeke M. Loiseau S. Hermann E. Dombrowicz D. et al. Human
723	[07]	Ecginand P, Driss V, Delocke W, Loiseau S, Hermann E, Doniorowicz D, et al. Human Ecginophils Evert TNE a and Granzyme A Mediated Tymoricidal Activity toward
724		Colon Carcinoma Cells, Limmunol 2010:185:7443, 51
725		bttps://doi.org/10.4049/IIMMUNOL_1000446
720 727	[68]	Idos GE Kwok I Bonthala N Kysh I Gruber SR Ou C The Prognostic Implications
121 728	[00]	of Tumor Infiltrating I ymphocytes in Colorectal Cancer: A Systematic Paview and
729		Meta-Analysis Sci Reports 2020 101 2020:10:1_14 https://doi.org/10.1038/s/1598_
,		men margas, ser reports 2020 101 2020,10.1 17. https://doi.org/10.1030/3413/0-

730		020-60255-4.
731	[69]	Boursi B, Mamtani R, Hwang WT, Haynes K, Yang YX. A Risk Prediction Model for
732		Sporadic CRC Based on Routine Lab Results. Dig Dis Sci 2016;61:2076–86.
733		https://doi.org/10.1007/S10620-016-4081-X/TABLES/4.
734	[70]	Goshen R, Mizrahi B, Akiva P, Kinar Y, Choman E, Shalev V, et al. Predicting the
735		presence of colon cancer in members of a health maintenance organisation by
736		evaluating analytes from standard laboratory records. Br J Cancer 2017 1167
737		2017;116:944-50. https://doi.org/10.1038/bjc.2017.53.
738	[71]	Siedlinski M, Jozefczuk E, Xu X, Teumer A, Evangelou E, Schnabel RB, et al.
739		Siedlinski et al White Blood Cells and Blood Pressure Indices. Circulation
740		2020;141:1307. https://doi.org/10.1161/CIRCULATIONAHA.119.045102.
741	[72]	Welsh C, Welsh P, Mark PB, Celis-Morales CA, Lewsey J, Gray SR, et al. Association
742		of total and differential leukocyte counts with cardiovascular disease and mortality in
743		the UK Biobank. Arterioscler Thromb Vasc Biol 2018;38:1415–23.
744		https://doi.org/10.1161/ATVBAHA.118.310945.
745		
746		

FIGURES for "Investigating the effect of circulating immune cell counts on colorectal cancer risk"



¹Chen et al. (https://doi.org/10.1016/j.cell.2020.06.045); ²Huyghe et al. (https://doi.org/10.1038/s41588 018 0286 6 & http://dx.doi.org/10.1136/gutjnl-2020-321534); ³UK Biobank (https://doi.org/10.1038/s41586-018-0579-z)

Figure 1: Study design



Figure 2: MR and Cohort analysis of WBC count on overall colorectal cancer